High-Dose Iron Safe, Effective in Hemodialysis Patients High-Dose Iron Safe, Effective in Hemodialysis Patients
High-dose iron reduces the amount of erythropoiesis-stimulating agent needed to treat dialysis patients with anemia, with no rise in risk for infection or cardiovascular events, new research shows.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - October 26, 2018 Category: Consumer Health News Tags: Nephrology News Source Type: news

Humacyte launches Phase II vascular trauma Humacyl vessel trial
Humacyte said yesterday it launched a U.S. Phase II trial of its Humacyl investigational human acellular vessel exploring the systems’ use for vascular replacement or reconstruction in patients with life or limb-threatening vascular trauma. The Research Triangle Park, N.C.-based company said it hopes to enroll 40 adult patients at six U.S. sites for the trial, with patient monitoring extending out to 24 months. “As a world leader in trauma research, we are constantly exploring new and innovative approaches to treating life threatening injuries. We look forward to evaluating this bioengineered blood vessel in th...
Source: Mass Device - October 26, 2018 Category: Medical Devices Authors: Fink Densford Tags: Clinical Trials Featured Vascular Humacyte Source Type: news

NxStage touts home hemodialysis study data
NxStage Medical (NSDQ:NXTM) today released data from a study comparing home hemodialysis to traditional treatment in a skilled nursing facility, touting a lower risk of death and cardiovascular hospitalization for those treated more often with home hemodialysis. Full results from the trial are slated to be presented at the American Society of Nephrology Kidney Week 2018 Annual Meeting next week, the Lawrence, Mass.-based company said. Investigators analyzed data collected from 3,619 patients treated in skilled nursing facilities between 2011 and 2015, and found that patients treated more frequently at home experienced a 3...
Source: Mass Device - October 18, 2018 Category: Medical Devices Authors: Fink Densford Tags: Blood Management Clinical Trials NxStage Medical Inc. Source Type: news

Vascular Therapies raises $12m for drug-eluting vascular access implant
Vascular Therapies has raised $12.4 million from 29 investors as part of a $21.1 million round, according to a document filed last week with the SEC. The Cresskill, N.J.-based company is developing a sirolimus-eluting collagen implant for patients with end-stage renal disease. The bioresorbable drug-delivery system is designed to keep open a portal of entry into a patient’s vascular system for hemodialysis. Get the full story at our sister site, Drug Delivery Business News. The post Vascular Therapies raises $12m for drug-eluting vascular access implant appeared first on MassDevice. (Source: Mass Device)
Source: Mass Device - October 15, 2018 Category: Medical Devices Authors: Sarah Faulkner Tags: Featured Funding Roundup Pharmaceuticals Vascular vasculartherapies Source Type: news

Ultrasound Can Predict Success of AV Fistula for Hemodialysis
Blood flow, diameter, and depth predict unassisted, overall maturation (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - October 12, 2018 Category: Cancer & Oncology Tags: Nephrology, Oncology, Radiology, Surgery, Journal, Source Type: news

Ultrasound Can Predict Success of AV Fistula for Hemodialysis
FRIDAY, Oct. 12, 2018 -- Detection of arteriovenous fistula (AVF) blood flow, diameter, and depth on ultrasound can predict AVF clinical maturation, according to a study published online Oct. 11 in the Journal of the American Society of... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - October 12, 2018 Category: Pharmaceuticals Source Type: news

Study: Online positive psychology exercises improve quality of life in hemodialysis patients
(University of Illinois at Urbana-Champaign) Patients with depression who used tablet computers to complete brief positive psychology exercises online several times a week scored lower on depressive symptoms and reported that they felt better able to cope with their kidney disease by the end of the five-week pilot study, led by University of Illinois social work professor Rosalba Hernandez. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - October 10, 2018 Category: International Medicine & Public Health Source Type: news

Rockwell Medical Appoints VP, Strategic Accounts
WIXOM, Mich., Oct. 1, 2018 -- (Healthcare Sales & Marketing Network) -- Rockwell Medical, Inc. (NASDAQ: RMTI) (the "Company" or "Rockwell Medical") today announced that Anne Boardman has been appointed Vice President, Strategic Account... Biopharmaceuticals, Personnel Rockwell Medical, Triferic, ferric pyrophosphate, hemodialysis (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - October 1, 2018 Category: Pharmaceuticals Source Type: news

Ethanol locks in catheters for dialysis may prevent sepsis
This Expert commentary, of a meta-analysis that reported ethanol lock is effective in reducing catheter-related bloodstream infection in haemodialysis patients, notes that further research is required before specific recommendations on ethanol locks can be made. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - September 28, 2018 Category: Consumer Health News Source Type: news

What Causes Hyperkalemia?
Discussion Potassium (K+) is an alkali metal (Group 1 of periodic table with Hydrogen, Lithium and Sodium) with an anatomic number of 19. Its chemical symbol K, comes from the medieval Latin, kalium which means potash (mainly potassium carbonate or potassium hydroxide), the substance it was first isolated from. Potassium is an important cation and it mainly resides in the intracellular fluid with only a small amount in the extracellular fluid. Potassium regulates cell volume, pH and enzyme functions. Hyperkalemia is defined as a potassium level > 5.5 mEq/L in children and > 6.0 mEq/L in newborns. Hyperkalemia inc...
Source: PediatricEducation.org - September 24, 2018 Category: Pediatrics Authors: pediatriceducationmin Tags: Uncategorized Source Type: news

Antimicrobial lock solutions for preventing catheterrelated infections in haemodialysis
This systematic review of 39 studies (n=4216) found antibiotic antimicrobial and combined (antibiotic ‐non antibiotic) lock solutions (LSs) decreased incidence of catheter‐related infection compared to control LSs. The effect on thrombosis incidence is uncertain for all antimicrobial LSs. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - September 12, 2018 Category: Consumer Health News Source Type: news

How sensors are helping hemodialysis move into the home
Providing advanced medical care in a patient’s home once required the help of trained professionals. No longer – new sensor technology is enabling a massive migration from hospitals to home care environments. Outset Medical’s Tablo home hemodialysis platform features a streamlined touchscreen interface and a small size. But the real core of its effectiveness lies in its sensors. [Image courtesy of Outset Medical] Medtech is on the move again. New technological advances are enabling systems that have, for years, been shackled to hospitals and clinics, to travel home with their users. For decades, hemodialysis sys...
Source: Mass Device - September 11, 2018 Category: Medical Devices Authors: Fink Densford Tags: Dialysis mHealth (Mobile Health) Outset Medical teconnectivity Source Type: news

Investors & #039; Faith in Outset Overwhelming with Whopping $132M round
When Leslie Trigg took the helm of Outset Medical in 2013, she helped lead a $60 million series B round. The San Jose-based company was also working to get the Tablo Hemodialysis system, a device that simplifies dialysis procedures, on the market. But oh, how things have changed. Outset Medical has seen Tablo gain a nod from the FDA in 2015 and has even seen a surge in investor and consumer interest in the device. Earlier this week, Outset Medical executives revealed the company closed on a $132 million a series D equity round. The round was backed by some heavy hitters and led by new investor Mubadala Investment Company, ...
Source: MDDI - August 29, 2018 Category: Medical Devices Authors: Omar Ford Tags: Business Source Type: news

Outset Medical closes $132m Series D funding round
Outset Medical said today it raised $132 million in a Series D round of equity financing, with funds slated to accelerate the commercial expansion of its Tablo hemodialysis system. The San Jose, Calif.-based company develops and produces the Tablo hemodialysis system, an all-in-1 dialysis machine designed to handle water purification and dialysate production and be used in a variety of different settings. The round was led by the newly invested Mubadala Investment Company and joined by existing investors Baxter Ventures, Fidelity Management and Research Company, Partner Fund Management LP, Perceptive Advisors, funds advise...
Source: Mass Device - August 28, 2018 Category: Medical Devices Authors: Fink Densford Tags: Blood Management Business/Financial News Funding Roundup Outset Medical Source Type: news

Vascular Graft Solutions ’ aneurysm graft used in hemodialysis patients
  Vascular Graft Solutions’ Frame external support Vascular Graft Solutions has reported the first clinical use of its Frame external support technology in high-flow arteriovenous (AV) fistulas. The first five cases were performed by Dr. Vladimir Matoussevitch from Cologne University Hospital in Germany. The braided cobalt chrome, kink-resistant external support was designed for autologous vein grafts in bypass or reconstruction of peripheral arterial blood vessels. Mattoussevitch used them to prevent high-flow AV fistula and aneurysmal enlargement complications, which are common in patients undergoing routine...
Source: Mass Device - August 20, 2018 Category: Medical Devices Authors: Nancy Crotti Tags: Blog Vascular vasculargraftsolutions Source Type: news